PDB26 ESTIMATED RENAL AND CARDIOVASCULAR OUTCOMES AND COST OFFSETS IN PATIENTS WITH TYPE 2 DIABETES (T2D) AND DIABETIC NEPHROPATHY (DKD) TREATED WITH CANAGLIFLOZIN

May 1, 2020, 00:00 AM
10.1016/j.jval.2020.04.214
https://www.valueinhealthjournal.com/article/S1098-3015(20)30402-2/fulltext
Section Title :
Section Order : 10072
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)30402-2&doi=10.1016/j.jval.2020.04.214
HEOR Topics :
Tags :
Regions :